# FDA Rejects Promising Cancer Drug Developed in China

Source: [MedPageToday.com - medical news for physicians](https://www.medpagetoday.com/hematologyoncology/lungcancer/123904) · 2026-11-16 · Medicine
Page: https://themorning.science/story/fda-rejects-promising-cancer-drug-developed-in-china-08c6f28cb82e750c
Kind: business · Impact: medium

## In brief

- The FDA declined to approve an investigational PD-1/VEGF bispecific antibody for an indication in non-small cell lung cancer (NSCLC), according to drugmaker Summit Therapeutics.
- The drug was developed in China and is described by MedPage Today as closely watched.
- The source says the drug could soon advance, but the available text does not give details on next steps.

## Why it matters

Regulatory decisions determine which experimental cancer therapies reach patients, and this rejection of a closely watched bispecific antibody shows how such candidates face scrutiny when they are developed abroad.

## Timeline

- 2026-11-16: Summit Therapeutics announced that the FDA declined to approve the drug for NSCLC

## Coverage

- [FDA Rejects Promising Cancer Drug Developed in China](https://www.medpagetoday.com/hematologyoncology/lungcancer/123904) — MedPageToday.com - medical news for physicians, 2026-11-16

Tags: fda, lung cancer, nsclc, pd-1, vegf, bispecific antibody

---

Brief generated by AI (claude-haiku-5-5) from the reporting listed under Coverage. Headlines belong to their publishers. The Morning Science – https://themorning.science
